Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Changing horses (endpoints) midstream (trial)? Discussing rationale for LLY's changing the EXPEDITION3 study from co-primary endpoints of change in cognition and function to just cognition.

Ticker(s): LLY, BIIB

Who's the expert?

Name: Dr Paul Aisen - MD

Institution: USC


  • Founding Director of USC Alzheimer's Therapeutic Research Institute
  • Designed and directed multicenter therapeutic trials and had led basic research studies on therapeutic targets and biomarkers
  • Has conducted therapeutic research on Alzheimer’s disease for the past two decades; has published extensively in peer reviewed journals

Interview Questions

Please discuss the findings of this study looking at cognitive and functional progression during this 18 month study.

Added By: joe_mccann

In light of this study, how much better understood is the course of disease in Alzheimer's understood?

Added By: joe_mccann

Why do you think the FDA was reluctant to embrace this study design change? Do you think it was due to a lack of robustness in the data or more a clinical trial integrity issue.

Added By: joe_mccann

Do other Alzheimer trials have supporting evidence of what was seen in this study? Has that analysis been published anywhere?

Added By: joe_mccann

Based on the changes to EXPEDITION3 how does that impact your view of solanezumab's chances for success?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.